Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement Ingredients Should Meet GRAS Standard - FDA's Lake

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement ingredients should adhere to the "generally recognized as safe" standard applicable to conventional food ingredients even though it is not required under DSHEA, FDA Center for Food Safety & Applied Nutrition's Robert Lake, PhD, advised at a Food & Drug Law Institute seminar on dietary ingredients in Washington, D.C. Nov. 8.

You may also be interested in...



"Functional foods" mfrs. group developing structure/function claims proposal comments.

NEW DIETARY INGREDIENTS ASSOCIATION TO FOCUS ON "FUNCTIONAL FOODS" and the furthering of research on the interaction between food components and disease reduction or prevention. The Research-based Dietary Ingredients Association (RbDIA) will undertake a multi-faceted agenda to represent the interests of manufacturers and developers of "functional foods." The association hopes to facilitate communication between, pharmaceutical, dietary supplement and food manufacturers that are developing functional food products.

Commission rejects evidence summaries in supplement claims notification.

SUPPLEMENT "STATEMENT OF AFFIRMATION" FOR SAFETY/EFFICACY ADVISED by the President's Commission on Dietary Supplement Labels final report issued Nov. 24 at the group's last meeting. Dietary supplement manufacturers voluntarily "should provide statements of affirmation that they have substantiation for the statement of nutritional support and that the product does not represent a significant or unreasonable risk of illness under conditions of use recommended or suggested in labeling," either in the notification letter to FDA required for all structure/function claims by the Dietary Supplement Health & Education Act or in a separate public notice, the report states.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS090568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel